Skip to main content
Top
Published in: Diagnostic Pathology 1/2012

Open Access 01-12-2012 | Research

Can p63 serve as a biomarker for giant cell tumor of bone? A Moroccan experience

Authors: Nawal Hammas, Chbani Laila, Alaoui Lamrani My Youssef, El Fatemi Hind, Taoufiq Harmouch, Tizniti Siham, Amarti Afaf

Published in: Diagnostic Pathology | Issue 1/2012

Login to get access

Abstract

Background

Multinucleated giant cell-containing tumors and pseudotumors of bone represent a heterogeneous group of benign and malignant lesions. Differential diagnosis can be challenging, particularly in instances of limited sampling. The purpose of this study was to evaluate the contribution of the P63 in the positive and differential diagnosis of giant cell tumor of bone.

Methods

This study includes 48 giant cell-containing tumors and pseudotumors of bone. P63 expression was evaluated by immunohistochemistry. Data analysis was performed using Epi-info software and SPSS software package (version 17).

Results

Immunohistochemical analysis showed a P63 nuclear expression in all giant cell tumors of bone, in 50% of osteoid osteomas, 40% of aneurysmal bone cysts, 37.5% of osteoblastomas, 33.3% of chondromyxoide fibromas, 25% of non ossifiant fibromas and 8.3% of osteosarcomas. Only one case of chondroblastoma was included in this series and expressed p63. No P63 immunoreactivity was detected in any of the cases of central giant cell granulomas or langerhans cells histiocytosis. The sensitivity and negative predictive value (NPV) of P63 immunohistochemistry for the diagnosis of giant cell tumor of bone were 100%. The specificity and positive predictive value (PPV) were 74.42% and 59.26% respectively.

Conclusions

This study found not only that GCTOB expresses the P63 but it also shows that this protein may serve as a biomarker for the differential diagnosis between two morphologically similar lesions particularly in instances of limited sampling. Indeed, P63 expression seems to differentiate between giant cell tumor of bone and central giant cell granuloma since the latter does not express P63. Other benign and malignant giant cell-containing lesions express P63, decreasing its specificity as a diagnostic marker, but a strong staining was seen, except a case of chondroblastoma, only in giant cell tumor of bone. Clinical and radiological confrontation remains essential for an accurate diagnosis.

Virtual slides

The virtual slide(s) for this article can be found here: http://​www.​diagnosticpathol​ogy.​diagnomx.​eu/​vs/​1838562590777252​.
Appendix
Available only for authorised users
Literature
1.
go back to reference Rosenberg AE, Nielsen GP: Giant cell containing lesions of bone and their differential diagnosis. Curr Diagn Pathol. 2001, 7: 235-246. 10.1054/cdip.2001.0080.CrossRef Rosenberg AE, Nielsen GP: Giant cell containing lesions of bone and their differential diagnosis. Curr Diagn Pathol. 2001, 7: 235-246. 10.1054/cdip.2001.0080.CrossRef
2.
go back to reference Jaffee HL, Lichtenstein L, Portis RB: Giant cell tumour of bone. Its pathologic appearance, grading, supposed variants and treatment. Arch Pathol. 1940, 30: 993-1013. Jaffee HL, Lichtenstein L, Portis RB: Giant cell tumour of bone. Its pathologic appearance, grading, supposed variants and treatment. Arch Pathol. 1940, 30: 993-1013.
3.
go back to reference de la Roza G: p63 Expression in Giant Cell–Containing Lesions of Bone and Soft Tissue. Arch Pathol Lab Med. 2011, 135: 776-779.PubMed de la Roza G: p63 Expression in Giant Cell–Containing Lesions of Bone and Soft Tissue. Arch Pathol Lab Med. 2011, 135: 776-779.PubMed
4.
go back to reference Dickson BC, Shu-Qiu L, Wunder JS, Ferguson PC, Eslami B, Werier JA, Turcotte RE, Kandel RA: Giant cell tumor of bone express p63. Mod Pathol. 2008, 21: 369-375. 10.1038/modpathol.2008.29.CrossRefPubMed Dickson BC, Shu-Qiu L, Wunder JS, Ferguson PC, Eslami B, Werier JA, Turcotte RE, Kandel RA: Giant cell tumor of bone express p63. Mod Pathol. 2008, 21: 369-375. 10.1038/modpathol.2008.29.CrossRefPubMed
5.
go back to reference Fletcher CDM, Unni KK, Mertens F: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. 2002, Lyon: IARC Press, 310-312. Fletcher CDM, Unni KK, Mertens F: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. 2002, Lyon: IARC Press, 310-312.
6.
go back to reference Lee CH, Inigo E, Kristin CJ, Subbaya S, Shirley XZ, Sushama V, Montgomery KD, Nielsen TO, van de Rijn M, West RB: Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the bone. Mod Pathol. 2008, 21: 531-539. 10.1038/modpathol.3801023.CrossRefPubMed Lee CH, Inigo E, Kristin CJ, Subbaya S, Shirley XZ, Sushama V, Montgomery KD, Nielsen TO, van de Rijn M, West RB: Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the bone. Mod Pathol. 2008, 21: 531-539. 10.1038/modpathol.3801023.CrossRefPubMed
7.
go back to reference Mendenhall WM, Zlotecki RA, Scarborough MT, Gibbs CP, Mendenhall NP: Giant cell tumor of bone. Am J Clin Oncol. 2006, 29: 96-99. 10.1097/01.coc.0000195089.11620.b7.CrossRefPubMed Mendenhall WM, Zlotecki RA, Scarborough MT, Gibbs CP, Mendenhall NP: Giant cell tumor of bone. Am J Clin Oncol. 2006, 29: 96-99. 10.1097/01.coc.0000195089.11620.b7.CrossRefPubMed
8.
go back to reference Little NA, Jochemsen AG: Molecules in focus: P63. Int J Biochem Cell Biol. 2002, 34: 6-9. 10.1016/S1357-2725(01)00086-3.CrossRefPubMed Little NA, Jochemsen AG: Molecules in focus: P63. Int J Biochem Cell Biol. 2002, 34: 6-9. 10.1016/S1357-2725(01)00086-3.CrossRefPubMed
9.
go back to reference Vincenzo G, Vincenzo DL: Role of p63 in cancer development. Biochim Biophys Acta. 2011, 1816 (1): 57-66. Vincenzo G, Vincenzo DL: Role of p63 in cancer development. Biochim Biophys Acta. 2011, 1816 (1): 57-66.
10.
go back to reference Nakatsuka SI, Harada H, Fujiyama H, Takeda K, Kitamura K, Kimura H, Nagano T, Ito M, Asada Y: An invasive adenocarcinoma of the accessory parotid gland: a rare example developing from a low-grade cribriform cystadenocarcinoma?. Diagn Pathol. 2011, 6: 122-10.1186/1746-1596-6-122.PubMedCentralCrossRefPubMed Nakatsuka SI, Harada H, Fujiyama H, Takeda K, Kitamura K, Kimura H, Nagano T, Ito M, Asada Y: An invasive adenocarcinoma of the accessory parotid gland: a rare example developing from a low-grade cribriform cystadenocarcinoma?. Diagn Pathol. 2011, 6: 122-10.1186/1746-1596-6-122.PubMedCentralCrossRefPubMed
11.
go back to reference Weinstein MH, Signoretti S, Loda M: Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Mod Pathol. 2002, 15 (12): 1302-1308. 10.1097/01.MP.0000038460.95912.6E.CrossRefPubMed Weinstein MH, Signoretti S, Loda M: Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Mod Pathol. 2002, 15 (12): 1302-1308. 10.1097/01.MP.0000038460.95912.6E.CrossRefPubMed
12.
go back to reference Barbareschi M, Pecciarini L, Cangi MG, Macrì E, Rizzo A, Viale G, Doglioni C: p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol. 2001, 25 (8): 1054-1060. 10.1097/00000478-200108000-00010.CrossRefPubMed Barbareschi M, Pecciarini L, Cangi MG, Macrì E, Rizzo A, Viale G, Doglioni C: p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol. 2001, 25 (8): 1054-1060. 10.1097/00000478-200108000-00010.CrossRefPubMed
13.
go back to reference Srinivasan M, Parwani AV: Diagnostic utility of p63/P501S double sequential immunohistochemical staining in differentiating urothelial carcinoma from prostate carcinoma. Diagn Pathol. 2011, 6: 67-10.1186/1746-1596-6-67.PubMedCentralCrossRefPubMed Srinivasan M, Parwani AV: Diagnostic utility of p63/P501S double sequential immunohistochemical staining in differentiating urothelial carcinoma from prostate carcinoma. Diagn Pathol. 2011, 6: 67-10.1186/1746-1596-6-67.PubMedCentralCrossRefPubMed
14.
go back to reference Quan Z, Hong C, Hongkai Z, Yiding H, Honggang L: Increased numbers of P63-positive/CD117-positive cells in advanced adenoid cystic carcinoma give a poorer prognosis. Diagn Pathol. 2012, 7: 119-10.1186/1746-1596-7-119.CrossRef Quan Z, Hong C, Hongkai Z, Yiding H, Honggang L: Increased numbers of P63-positive/CD117-positive cells in advanced adenoid cystic carcinoma give a poorer prognosis. Diagn Pathol. 2012, 7: 119-10.1186/1746-1596-7-119.CrossRef
15.
go back to reference Linden MD: Giant cell lesions of bone and soft tissues: diagnostic value of immunohistochemistry [abstract]. Mod Pathol. 2009, 22 (suppl 1s): 18A- Linden MD: Giant cell lesions of bone and soft tissues: diagnostic value of immunohistochemistry [abstract]. Mod Pathol. 2009, 22 (suppl 1s): 18A-
Metadata
Title
Can p63 serve as a biomarker for giant cell tumor of bone? A Moroccan experience
Authors
Nawal Hammas
Chbani Laila
Alaoui Lamrani My Youssef
El Fatemi Hind
Taoufiq Harmouch
Tizniti Siham
Amarti Afaf
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2012
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-7-130

Other articles of this Issue 1/2012

Diagnostic Pathology 1/2012 Go to the issue